BeiGene-Voyagers Innovation Fund Launches with Focus on Early-Stage Innovative Drug Investments

In March 2026, BeiGene Innovation Center (hereinafter referred to as “BIC”) and Voyagers Capital jointly announced the establishment of the “BeiGene-Voyagers Innovation Fund” (the specific name shall be subject to the name registered with the industry and commerce authorities) in Guangzhou, completing its first closing. Limited Partners (LPs) participating in this initial closing include leading enterprises in various specialized segments of the pharmaceutical industry invested by BIC, such as Boya Biolabs, Sansure Biotech, Haoyuan Chemexpress, PharmaBlock, Lummy Pharmaceutical, and HitGen.

The BeiGene-Voyagers Innovation Fund will focus on early-stage investment in innovative drugs. Leveraging the extensive incubation and investment expertise of BIC and Voyagers Capital, the fund will fully capitalize on its deep industrial resource advantages to drive the efficient translation and implementation of cutting-edge scientific achievements, empowering portfolio companies to accelerate their growth from technological breakthroughs to clinical applications.

Beigene is science-driven and has cultivated a vibrant entrepreneurial culture. We are committed not only to independent R&D innovation but also to supporting the industry’s shift toward source innovation, aiming to help entrepreneurs and innovators conduct critical scientific research and provide more affordable, innovative medicines to patients worldwide. To promote the development of China’s biotechnology sector, empower the pharmaceutical industry with new-quality productive forces, and enhance the translation of local original scientific achievements into applications, Beigene established the Beigene Bio-Island Innovation Center, with its core being the Venture Lab. Since its inception in 2021, the Venture Lab has built a 90-member entrepreneurial incubation team and has incubated multiple innovative enterprises. We support and accelerate highly differentiated, cutting-edge external innovations, helping scientists and entrepreneurs expedite the R&D of future-oriented transformative drugs to meet the medical needs of patients globally. By integrating external resources, the Venture Lab opens new pathways for exploring frontier, groundbreaking industry innovations.

Sansure Biotech Inc. is a provider of comprehensive “diagnosis-treatment integrated” solutions, centered on independently innovated genetic technologies and integrating reagents, instruments, quality control, third-party medical testing, consumer health, AI+biopharmaceuticals, and AI+bio-manufacturing. Committed to making life sciences accessible to all, the company is listed on the STAR Market (Stock Code: 688289) and has been ranked among the Top 100 Chinese Pharmaceutical Industrial Enterprises and the Top 100 Global Medical Device Companies. Sansure Biotech has developed over 1,000 products in fields such as infectious disease prevention and control, maternal and child health, blood safety, cancer prevention and control, companion diagnostics, and agricultural and pastoral technology. It has filled numerous technological gaps in the industry, achieved domestic substitution for imported products, served more than 160 countries and regions worldwide, and cumulatively provided testing products for over 3 billion person-times.

Shanghai Haoyuan Pharmachem Co., Ltd. (Stock Code: 688131), founded in 2006, specializes in the research and development of life science reagents for small molecule, large molecule, and novel modality drug discovery, as well as the drug development, process optimization, and commercial manufacturing of active pharmaceutical ingredients (APIs), intermediates, starting materials, and finished dosage forms. With innovation as its core driver, the company adopts a “Product + Service” model to pursue differentiated growth. It has established over ten R&D and production bases and leverages ten core technology platforms to build an integrated service platform covering the entire drug development and manufacturing chain—from starting materials and intermediates to APIs, biologics, and finished dosage forms. This enables the acceleration of support for more than 13,000 global partners throughout the full spectrum from preclinical stages to commercial production, making drug R&D more efficient, accelerating time-to-market, and ultimately benefiting human health at an earlier stage.

Beijing Cyagen Biosciences Research Institute Co., Ltd. was established in 2016 and possesses a comprehensive Good Laboratory Practice (GLP) qualification system covering NMPA, FDA, OECD, and PMDA standards. The company comprises multiple business divisions, including pharmaceutical R&D consulting, NMPA/FDA registration and filing, antibody drug discovery, AI-driven organoid drug screening and druggability evaluation, pharmacological and efficacy assessment, pharmacokinetic evaluation, non-clinical safety assessment, biological sample testing and companion diagnostic product development, as well as integrated production and R&D of radiopharmaceuticals. Leveraging a specialized research team and a rigorous quality management system, the company is committed to providing world-class non-clinical CRO services, enhancing the efficiency of scientific achievement translation, and accelerating the R&D process of innovative drugs.

Chongqing Lummy Pharmaceutical Co., Ltd. was established in 1999 and listed on the ChiNext Board of the Shenzhen Stock Exchange in 2009 (Stock Code: 300006). As one of the first 28 companies listed on the ChiNext Board, it was the first company from Chongqing to go public on this board. It is a national high-tech enterprise engaged in research and development, production, and sales, with business segments covering pharmaceutical manufacturing, pharmaceutical innovation, pharmaceutical distribution, medical devices, and health services.

Chengdu HitGen Co., Ltd. (Stock Code: 688222) is committed to building an internationally leading innovative biopharmaceutical enterprise. The company focuses on the discovery and optimization of novel small-molecule and nucleic acid drugs, having established an internationally leading DNA-Encoded Library (DEL) technology platform, while also expanding its core technological platforms in Fragment-Based and Structure-Based Drug Design (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).

Voyagers Capital, established in 2022, is a venture capital firm specializing in the healthcare and medical sectors. The Voyagers team possesses extensive experience in early-stage investment in innovative drugs, with representative incubated portfolio companies including GenFleet Therapeutics (02595.HK) and Pumus Biopharma (acquired by BioNTech in 2024).